Share Price and Basic Stock Data
Last Updated: October 9, 2025, 12:59 am
| PEG Ratio | 1.86 |
|---|
Analyst Insight & Comprehensive Analysis
Fabino Enterprises Ltd, a pharmaceutical company, currently trades at a price of ₹24.2 with a market capitalization of ₹5.09 Cr. The company’s price-to-earnings ratio stands at 39.2, reflecting a premium valuation compared to the sector average of around 25x. Despite this, Fabino’s return on equity (ROE) at 3.08% and return on capital employed (ROCE) at 7.16% are below industry benchmarks, indicating potential inefficiencies in capital utilization. Furthermore, the company’s operating profit margin (OPM) of 0.94% is lower than the sector median of 15-20%, highlighting operational challenges.
On the positive side, Fabino boasts a healthy interest coverage ratio (ICR) of 3.08x, indicating its ability to service debt obligations comfortably. Additionally, the company’s strong promoter holding of 56.82% signifies a long-term commitment to the business. However, with a relatively high price-to-book value (P/BV) ratio of 1.22x and a low net profit margin of 0.13%, Fabino faces risks associated with overvaluation and limited profitability. Looking ahead, improving operational efficiency, expanding product lines, and enhancing research and development efforts could bolster Fabino’s competitiveness in the pharmaceutical sector.
In conclusion, while Fabino Enterprises Ltd exhibits certain financial strengths such as a solid promoter holding and healthy interest coverage, it also faces risks stemming from its subdued profitability metrics. Investors should closely monitor the company’s efforts to enhance operational performance and innovation to gauge its long-term growth potential accurately.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Fabino Enterprises Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 152 Cr. | 121 | 247/84.3 | 34.6 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.98 Cr. | 2.08 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,528 Cr. | 415 | 434/192 | 102 | 22.8 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 31.3 Cr. | 42.2 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 29.3 Cr. | 20.0 | 29.1/17.0 | 30.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 18,996.63 Cr | 1,173.56 | 51.08 | 192.71 | 0.33% | 16.15% | 14.90% | 6.18 |
Quarterly Result
| Metric | Mar 2021 | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.38 | 2.05 | 2.15 | 1.04 | 2.32 | 0.94 | 5.14 | 4.25 | 13.78 |
| Expenses | 2.15 | 2.11 | 2.00 | 1.03 | 2.30 | 0.87 | 5.10 | 4.21 | 13.65 |
| Operating Profit | 0.23 | -0.06 | 0.15 | 0.01 | 0.02 | 0.07 | 0.04 | 0.04 | 0.13 |
| OPM % | 9.66% | -2.93% | 6.98% | 0.96% | 0.86% | 7.45% | 0.78% | 0.94% | 0.94% |
| Other Income | 0.00 | 0.01 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.11 | 0.18 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.06 | 0.07 |
| Depreciation | 0.02 | 0.00 | 0.03 | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | 0.04 |
| Profit before tax | 0.21 | -0.05 | 0.12 | 0.01 | 0.00 | 0.06 | 0.01 | 0.07 | 0.20 |
| Tax % | 0.00% | 0.00% | 16.67% | 0.00% | 33.33% | 0.00% | 28.57% | 55.00% | |
| Net Profit | 0.21 | -0.05 | 0.10 | 0.01 | 0.00 | 0.05 | 0.00 | 0.05 | 0.09 |
| EPS in Rs | 1.75 | -0.42 | 0.48 | 0.05 | 0.00 | 0.24 | 0.00 | 0.24 | 0.43 |
Last Updated: May 31, 2025, 6:05 am
Below is a detailed analysis of the quarterly data for Fabino Enterprises Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 13.78 Cr.. The value appears strong and on an upward trend. It has increased from 4.25 Cr. (Sep 2024) to 13.78 Cr., marking an increase of 9.53 Cr..
- For Expenses, as of Mar 2025, the value is 13.65 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.21 Cr. (Sep 2024) to 13.65 Cr., marking an increase of 9.44 Cr..
- For Operating Profit, as of Mar 2025, the value is 0.13 Cr.. The value appears strong and on an upward trend. It has increased from 0.04 Cr. (Sep 2024) to 0.13 Cr., marking an increase of 0.09 Cr..
- For OPM %, as of Mar 2025, the value is 0.94%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.94%.
- For Other Income, as of Mar 2025, the value is 0.18 Cr.. The value appears strong and on an upward trend. It has increased from 0.11 Cr. (Sep 2024) to 0.18 Cr., marking an increase of 0.07 Cr..
- For Interest, as of Mar 2025, the value is 0.07 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.06 Cr. (Sep 2024) to 0.07 Cr., marking an increase of 0.01 Cr..
- For Depreciation, as of Mar 2025, the value is 0.04 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.02 Cr. (Sep 2024) to 0.04 Cr., marking an increase of 0.02 Cr..
- For Profit before tax, as of Mar 2025, the value is 0.20 Cr.. The value appears strong and on an upward trend. It has increased from 0.07 Cr. (Sep 2024) to 0.20 Cr., marking an increase of 0.13 Cr..
- For Tax %, as of Mar 2025, the value is 55.00%. The value appears to be increasing, which may not be favorable. It has increased from 28.57% (Sep 2024) to 55.00%, marking an increase of 26.43%.
- For Net Profit, as of Mar 2025, the value is 0.09 Cr.. The value appears strong and on an upward trend. It has increased from 0.05 Cr. (Sep 2024) to 0.09 Cr., marking an increase of 0.04 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.43. The value appears strong and on an upward trend. It has increased from 0.24 (Sep 2024) to 0.43, marking an increase of 0.19.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: June 16, 2025, 1:30 pm
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Sales | 2.76 | 7.52 | 3.06 | 4.19 | 3.36 | 6.01 | 18.04 |
| Expenses | 2.44 | 7.20 | 2.99 | 4.09 | 3.33 | 6.19 | 17.87 |
| Operating Profit | 0.32 | 0.32 | 0.07 | 0.10 | 0.03 | -0.18 | 0.17 |
| OPM % | 11.59% | 4.26% | 2.29% | 2.39% | 0.89% | -3.00% | 0.94% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.29 | 0.29 |
| Interest | 0.29 | 0.20 | 0.01 | 0.01 | 0.01 | 0.02 | 0.13 |
| Depreciation | 0.03 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.07 |
| Profit before tax | 0.00 | 0.10 | 0.04 | 0.07 | 0.01 | 0.06 | 0.26 |
| Tax % | 30.00% | 25.00% | 28.57% | 0.00% | 16.67% | 50.00% | |
| Net Profit | 0.00 | 0.07 | 0.03 | 0.05 | 0.01 | 0.05 | 0.13 |
| EPS in Rs | 0.00 | 4.67 | 0.25 | 0.24 | 0.05 | 0.24 | 0.62 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -57.14% | 66.67% | -80.00% | 400.00% | 160.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 123.81% | -146.67% | 480.00% | -240.00% |
Fabino Enterprises Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 63% |
| TTM: | 200% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 13% |
| 3 Years: | 38% |
| TTM: | 160% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 1% |
| 1 Year: | 0% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | 2% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 3:30 pm
Balance Sheet
Last Updated: July 25, 2025, 1:19 pm
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.15 | 0.15 | 1.20 | 2.10 | 2.10 | 2.10 | 2.10 |
| Reserves | 0.45 | 0.52 | 0.10 | 2.00 | 2.01 | 2.06 | 2.19 |
| Borrowings | 2.52 | 1.08 | 0.31 | 0.05 | 0.41 | 0.84 | 1.61 |
| Other Liabilities | 5.43 | 1.83 | 0.65 | 0.48 | 0.50 | 4.50 | 7.11 |
| Total Liabilities | 8.55 | 3.58 | 2.26 | 4.63 | 5.02 | 9.50 | 13.01 |
| Fixed Assets | 0.10 | 0.08 | 0.16 | 0.17 | 0.15 | 0.24 | 0.46 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 |
| Other Assets | 8.45 | 3.50 | 2.10 | 4.46 | 4.87 | 9.21 | 12.50 |
| Total Assets | 8.55 | 3.58 | 2.26 | 4.63 | 5.02 | 9.50 | 13.01 |
Below is a detailed analysis of the balance sheet data for Fabino Enterprises Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 2.10 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 2.10 Cr..
- For Reserves, as of Mar 2025, the value is 2.19 Cr.. The value appears strong and on an upward trend. It has increased from 2.06 Cr. (Mar 2024) to 2.19 Cr., marking an increase of 0.13 Cr..
- For Borrowings, as of Mar 2025, the value is 1.61 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 0.84 Cr. (Mar 2024) to 1.61 Cr., marking an increase of 0.77 Cr..
- For Other Liabilities, as of Mar 2025, the value is 7.11 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.50 Cr. (Mar 2024) to 7.11 Cr., marking an increase of 2.61 Cr..
- For Total Liabilities, as of Mar 2025, the value is 13.01 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9.50 Cr. (Mar 2024) to 13.01 Cr., marking an increase of 3.51 Cr..
- For Fixed Assets, as of Mar 2025, the value is 0.46 Cr.. The value appears strong and on an upward trend. It has increased from 0.24 Cr. (Mar 2024) to 0.46 Cr., marking an increase of 0.22 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.05 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.05 Cr..
- For Other Assets, as of Mar 2025, the value is 12.50 Cr.. The value appears strong and on an upward trend. It has increased from 9.21 Cr. (Mar 2024) to 12.50 Cr., marking an increase of 3.29 Cr..
- For Total Assets, as of Mar 2025, the value is 13.01 Cr.. The value appears strong and on an upward trend. It has increased from 9.50 Cr. (Mar 2024) to 13.01 Cr., marking an increase of 3.51 Cr..
Notably, the Reserves (2.19 Cr.) exceed the Borrowings (1.61 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Free Cash Flow | -2.20 | -0.76 | -0.24 | 0.05 | -0.38 | -1.02 | -1.44 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 338.55 | 113.09 | 158.64 | 125.44 | 274.84 | 377.75 | 177.43 |
| Inventory Days | 988.71 | 15.36 | 62.61 | 174.83 | 147.24 | 88.59 | 26.56 |
| Days Payable | 1,024.81 | 77.34 | 63.94 | 34.76 | 45.78 | 294.40 | 152.06 |
| Cash Conversion Cycle | 302.45 | 51.11 | 157.31 | 265.51 | 376.29 | 171.94 | 51.93 |
| Working Capital Days | 19.84 | 51.93 | 165.80 | 292.70 | 444.30 | 282.40 | 103.21 |
| ROCE % | 12.32% | 2.98% | 2.78% | 0.46% | 1.68% | 7.16% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 |
|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.29 | 0.17 | 0.05 |
| Diluted EPS (Rs.) | 0.29 | 0.17 | 0.05 |
| Cash EPS (Rs.) | 0.67 | 0.37 | 0.20 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 20.02 | 19.73 | 19.59 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 20.02 | 19.73 | 19.59 |
| Revenue From Operations / Share (Rs.) | 85.89 | 100.39 | 16.00 |
| PBDIT / Share (Rs.) | 1.90 | 0.62 | 0.22 |
| PBIT / Share (Rs.) | 1.51 | 0.41 | 0.07 |
| PBT / Share (Rs.) | 0.89 | 0.23 | 0.05 |
| Net Profit / Share (Rs.) | 0.29 | 0.17 | 0.05 |
| NP After MI And SOA / Share (Rs.) | 0.29 | 0.17 | 0.05 |
| PBDIT Margin (%) | 2.21 | 0.62 | 1.42 |
| PBIT Margin (%) | 1.76 | 0.41 | 0.47 |
| PBT Margin (%) | 1.04 | 0.23 | 0.36 |
| Net Profit Margin (%) | 0.33 | 0.16 | 0.32 |
| NP After MI And SOA Margin (%) | 0.33 | 0.16 | 0.32 |
| Return on Networth / Equity (%) | 1.45 | 0.86 | 0.26 |
| Return on Capital Employeed (%) | 5.29 | 1.59 | 0.35 |
| Return On Assets (%) | 0.34 | 0.23 | 0.21 |
| Long Term Debt / Equity (X) | 0.42 | 0.30 | 0.09 |
| Total Debt / Equity (X) | 0.42 | 0.30 | 0.09 |
| Asset Turnover Ratio (%) | 1.09 | 2.07 | 0.00 |
| Current Ratio (X) | 1.46 | 1.51 | 10.73 |
| Quick Ratio (X) | 1.36 | 1.37 | 8.07 |
| Interest Coverage Ratio (X) | 3.08 | 3.48 | 12.01 |
| Interest Coverage Ratio (Post Tax) (X) | 1.47 | 1.95 | 3.72 |
| Enterprise Value (Cr.) | 6.69 | 9.52 | 6.46 |
| EV / Net Operating Revenue (X) | 0.37 | 0.45 | 1.92 |
| EV / EBITDA (X) | 16.78 | 72.62 | 135.37 |
| MarketCap / Net Operating Revenue (X) | 0.28 | 0.39 | 1.87 |
| Price / BV (X) | 1.22 | 2.01 | 1.53 |
| Price / Net Operating Revenue (X) | 0.28 | 0.39 | 1.88 |
| EarningsYield | 0.01 | 0.00 | 0.00 |
After reviewing the key financial ratios for Fabino Enterprises Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 5. It has increased from 0.17 (Mar 24) to 0.29, marking an increase of 0.12.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 5. It has increased from 0.17 (Mar 24) to 0.29, marking an increase of 0.12.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.67. This value is below the healthy minimum of 3. It has increased from 0.37 (Mar 24) to 0.67, marking an increase of 0.30.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 20.02. It has increased from 19.73 (Mar 24) to 20.02, marking an increase of 0.29.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 20.02. It has increased from 19.73 (Mar 24) to 20.02, marking an increase of 0.29.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 85.89. It has decreased from 100.39 (Mar 24) to 85.89, marking a decrease of 14.50.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 1.90. This value is below the healthy minimum of 2. It has increased from 0.62 (Mar 24) to 1.90, marking an increase of 1.28.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.51. This value is within the healthy range. It has increased from 0.41 (Mar 24) to 1.51, marking an increase of 1.10.
- For PBT / Share (Rs.), as of Mar 25, the value is 0.89. This value is within the healthy range. It has increased from 0.23 (Mar 24) to 0.89, marking an increase of 0.66.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 2. It has increased from 0.17 (Mar 24) to 0.29, marking an increase of 0.12.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.29. This value is below the healthy minimum of 2. It has increased from 0.17 (Mar 24) to 0.29, marking an increase of 0.12.
- For PBDIT Margin (%), as of Mar 25, the value is 2.21. This value is below the healthy minimum of 10. It has increased from 0.62 (Mar 24) to 2.21, marking an increase of 1.59.
- For PBIT Margin (%), as of Mar 25, the value is 1.76. This value is below the healthy minimum of 10. It has increased from 0.41 (Mar 24) to 1.76, marking an increase of 1.35.
- For PBT Margin (%), as of Mar 25, the value is 1.04. This value is below the healthy minimum of 10. It has increased from 0.23 (Mar 24) to 1.04, marking an increase of 0.81.
- For Net Profit Margin (%), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 5. It has increased from 0.16 (Mar 24) to 0.33, marking an increase of 0.17.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 0.33. This value is below the healthy minimum of 8. It has increased from 0.16 (Mar 24) to 0.33, marking an increase of 0.17.
- For Return on Networth / Equity (%), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 15. It has increased from 0.86 (Mar 24) to 1.45, marking an increase of 0.59.
- For Return on Capital Employeed (%), as of Mar 25, the value is 5.29. This value is below the healthy minimum of 10. It has increased from 1.59 (Mar 24) to 5.29, marking an increase of 3.70.
- For Return On Assets (%), as of Mar 25, the value is 0.34. This value is below the healthy minimum of 5. It has increased from 0.23 (Mar 24) to 0.34, marking an increase of 0.11.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has increased from 0.30 (Mar 24) to 0.42, marking an increase of 0.12.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.42. This value is within the healthy range. It has increased from 0.30 (Mar 24) to 0.42, marking an increase of 0.12.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.09. It has decreased from 2.07 (Mar 24) to 1.09, marking a decrease of 0.98.
- For Current Ratio (X), as of Mar 25, the value is 1.46. This value is below the healthy minimum of 1.5. It has decreased from 1.51 (Mar 24) to 1.46, marking a decrease of 0.05.
- For Quick Ratio (X), as of Mar 25, the value is 1.36. This value is within the healthy range. It has decreased from 1.37 (Mar 24) to 1.36, marking a decrease of 0.01.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 3.08. This value is within the healthy range. It has decreased from 3.48 (Mar 24) to 3.08, marking a decrease of 0.40.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.47. This value is below the healthy minimum of 3. It has decreased from 1.95 (Mar 24) to 1.47, marking a decrease of 0.48.
- For Enterprise Value (Cr.), as of Mar 25, the value is 6.69. It has decreased from 9.52 (Mar 24) to 6.69, marking a decrease of 2.83.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.37. This value is below the healthy minimum of 1. It has decreased from 0.45 (Mar 24) to 0.37, marking a decrease of 0.08.
- For EV / EBITDA (X), as of Mar 25, the value is 16.78. This value exceeds the healthy maximum of 15. It has decreased from 72.62 (Mar 24) to 16.78, marking a decrease of 55.84.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.28, marking a decrease of 0.11.
- For Price / BV (X), as of Mar 25, the value is 1.22. This value is within the healthy range. It has decreased from 2.01 (Mar 24) to 1.22, marking a decrease of 0.79.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.28. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.28, marking a decrease of 0.11.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fabino Enterprises Ltd:
- Net Profit Margin: 0.33%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 5.29% (Industry Average ROCE: 16.15%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 1.45% (Industry Average ROE: 14.9%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.47
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.36
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 37.1 (Industry average Stock P/E: 51.08)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.42
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0.33%
About the Company - Qualitative Analysis
Fabino Enterprises Ltd. is a Public Limited Listed company incorporated on 27/10/2011 and has its registered office in the State of Haryana, India. Company's Corporate Identification Number(CIN) is L24100HR2011PLC114093 and registration number is 226781. Currently company belongs to the Industry of Pharmaceuticals. Company's Total Operating Revenue is Rs. 18.04 Cr. and Equity Capital is Rs. 2.10 Cr. for the Year ended 31/03/2025.
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Jeevan Vihar Extension Near, Shubham Garden, Sonipat Haryana 131001 | info@fabinolife.com www.fabinolife.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Aditya Jain | Managing Director |
| Mr. Arihant Jain | Non Executive Director |
| Mr. Sumit Malik | Non Executive Director |
| Mr. Kuldeep Singh Solanki | Independent Director |
| Mrs. Tesu Alakh | Independent Director |
| Mrs. Vandana Jain | Additional Director |
FAQ
What is the intrinsic value of Fabino Enterprises Ltd?
Fabino Enterprises Ltd's intrinsic value (as of 10 October 2025) is 19.02 which is 17.30% lower the current market price of 23.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹4.83 Cr. market cap, FY2025-2026 high/low of 39.0/22.8, reserves of ₹2.19 Cr, and liabilities of 13.01 Cr.
What is the Market Cap of Fabino Enterprises Ltd?
The Market Cap of Fabino Enterprises Ltd is 4.83 Cr..
What is the current Stock Price of Fabino Enterprises Ltd as on 10 October 2025?
The current stock price of Fabino Enterprises Ltd as on 10 October 2025 is 23.0.
What is the High / Low of Fabino Enterprises Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Fabino Enterprises Ltd stocks is 39.0/22.8.
What is the Stock P/E of Fabino Enterprises Ltd?
The Stock P/E of Fabino Enterprises Ltd is 37.1.
What is the Book Value of Fabino Enterprises Ltd?
The Book Value of Fabino Enterprises Ltd is 20.4.
What is the Dividend Yield of Fabino Enterprises Ltd?
The Dividend Yield of Fabino Enterprises Ltd is 0.00 %.
What is the ROCE of Fabino Enterprises Ltd?
The ROCE of Fabino Enterprises Ltd is 7.16 %.
What is the ROE of Fabino Enterprises Ltd?
The ROE of Fabino Enterprises Ltd is 3.08 %.
What is the Face Value of Fabino Enterprises Ltd?
The Face Value of Fabino Enterprises Ltd is 10.0.